Clinical Efficacy of Picotamide in Long-Term Treatment of Intermittent Claudication

Abstract

The clinical efficacy of picotamide was investigated in a randomized, double- blind, placebo-controlled study in patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification. Forty patients with a history of claudication for at least six months were admit ted to the study and were given either 3 x 300 mg tablets of picotamide (20 subjects) or three identical placebo tablets (20 subjects) for six months. The two groups of patients were similar in regard to clinical features and potential risk factors.

At the end of treatment painfree walking distance and systolic ankle-arm pressure ratio improved more in the picotamide than in the placebo group (p=0.05). Systolic ankle pressure curves, determined before and after the six- month treatment, showed a positive trend to a higher postexercise ankle pres sure and a faster return to the preexercise levels in the picotamide group; however, the difference was not statistically significant. Laboratory monitoring revealed a slight prolongation of bleeding time, a significant decrease in arachi donic acid-induced platelet aggregation, and an enhanced fibrinolysis with ab sence of interference with hemostasis in the picotamide group. One patient in the placebo group developed a major cardiovascular event (angina pectoris) during the study.

These results indicate that picotamide is an effective drug that may modify the natural course of intermittent claudication and associated vascular prob lems.

Get full access to this article

View all access options for this article.

References

Ross R. : The pathogenesis wall and atherosclerosis. Ann Rev Med 30:1-15, 1979.

Sinzinger H. , Fitscha P. , Peskar BA : Platelet half-life, plasma thromboxane B 2 and circulating endothelial cells in peripheral vascular disease. Angiology 37:112-118, 1986.

Hess H. , Mietaschk A. , Deichsel G. : Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet 23:415-419, 1985.

Deckmyn H. , Gresele P. , Vanhoutte E. , et al: Synergism of a thromboxane (TX) synthase inhibitor (TSI) and a TX receptor antagonist (TRA) in reducing platelet activation. Abstracts Xth International Congress on Thrombolysis and Haemostasis , July, 1985.

Schmutzler R. , Hartmann H. , Casale G. , et al: Picotamide: Effects on coagulation, fibrinolysis and platelet aggregation during prolonged administration in the aged. Age Ageing 7:246-250, 1978.

Coto V. , Carrieri P. , Cocozza M. , et al: Studio dell'attivita antipiastrinica della picotamide in pazienti con patologia vascolare cronica. Minerva Cardiol 34:601-604, 1986.

Siegel S. : Nonparametric Studies. New York: McGraw-Hill, 1956, pp 73-83.

Bounomeaux H. , Holditch T. , Hellemans H. , et al: Placebo-controlled, double-blind trial of ketaserin in the treatment of intermittent claudication . Lancet 2:1268-1271, 1985 .

Signorini GP , Salmistraro G. , Maraglino G. : Efficacy of indobufene in the treatment of intermittent claudication. Angiology 39:742-746, 1988.

10.

Arcan JC , Blanchard J. , Boissel JP : Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and prevention of its complications. Angiology 39:802-811, 1988.

11.

Antiplatelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 196:328-331, 1988.

12.

Bassen MG , Eschweger E. , Haguenan M. , et al: "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 14:5-11, 1983.